ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients.

E. Schrezenmeier,1 T. Doerner,2 O. Staeck,1 K. Budde,1 F. Halleck.1

1Nephrology, Charité, Berin, Germany
2Rheumatology, Charité, Berlin, Germany.

Meeting: 2016 American Transplant Congress

Abstract number: D144

Keywords: Antilymphocyte antibodies, Infection

Session Information

Date: Tuesday, June 14, 2016

Session Name: Poster Session D: Kidney Immunosuppression: Novel Agents

Session Time: 6:00pm-7:00pm

 Presentation Time: 6:00pm-7:00pm

Location: Halls C&D

Related Abstracts
  • Infectious Complications in ABO Incompatible Kidney Transplantation Recipient According to the Rituximab Dose
  • Incidence and Risk Factors for Infectious Complications in Liver Transplant Patients Converted to Everolimus

BACKGROUND:

Rituximab off-label use is common in solid organ transplantation. It is used in patients with antibody-mediated rejections, in AB0-incompatible renal transplantation, in pre-sensitized organ recipients or the treatment of recurrence of focal segmental glomerulosclerosis (FSGS). Long-term outcomes data especially regarding infectious complications are missing.

PATIENTS AND METHODS:

A retrospective single center observational study was conducted. 63 adult kidney-transplant recipients who have received rituximab between 2006 and 2014 were enrolled in the study. Patients received rituximab for AB0-incompatible renal transplantation, eecurrence of FSGS, antibody-mediated rejection or desensitization.

Age (years)

44 (20-70)

Gender (M/F)

38/35

Number of transplantations

1,30 ± 0,66

Anti-IL2R blocker induction therapy (Y/N)

33/30

Plasma exchange associated with rituximab (Y/N)

37/26

Steroid pulse associated with rituximab (Y/N)

56/63

Eculizumab associated with rituximab (Y/N)

2/61

IVIG associated with rituximab (Y/N)

20/42

Bortezomib associated with rituximab (Y/N)

15/48

RESULTS:

Median follow-up was 42 (1-109) months. The incidence of severe infections needing in hospital treatment was 57% overall. The median time between the first rituximab infusion and the first infection was 4 (1-48) months. Severe bacterial infections were observed in 44.4% of cases, severe viral infections in 7.9 % of cases, severe fungal in 4,8% of cases. Severe combined (viral, bacterial and fungal) infections 6.4% cases. Of the 7 patients (11.1%) who died in the observational period, 2 died from infectious complications. In the observational period there was one case of squamous cell carcinoma, no other malignancies were observed. Bacterial infections observed were due to sepsis with positive blood cultures (n=19), urinary tract infection (n=36), pneumonia (n=10), catheter-associated infection (n=2), erysipel skin infection (n=2), wound infection (n=2), colitis (n=2), otitis (n=2), sakroileitis (n=1) and atypical mycobacteriosis.

CONCLUSION:

Consistent with previous data a high proportion of infections were observed after rituximab use in kidney-transplant recipients. Most infections occur within six months after rituximab infusion. With more than 3 years of follow-up we were able to document a low incidence of secondary malignancies after rituximab use.

CITATION INFORMATION: Schrezenmeier E, Doerner T, Staeck O, Budde K, Halleck F. Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients. Am J Transplant. 2016;16 (suppl 3).

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Schrezenmeier E, Doerner T, Staeck O, Budde K, Halleck F. Incidence of Infectious Disease and Malignancies After Rituximab Therapy in Kidney-Transplant Recipients. [abstract]. Am J Transplant. 2016; 16 (suppl 3). https://atcmeetingabstracts.com/abstract/incidence-of-infectious-disease-and-malignancies-after-rituximab-therapy-in-kidney-transplant-recipients/. Accessed March 6, 2021.

« Back to 2016 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Role of Mitochondria, Metabolism and Inflammation: Pathways Influencing Short Term Outcomes Post-Renal Transplantation
    • Factors Influencing Creatinine Rise Following Donor Nephrectomy

    Visit Our Partner Sites

    American Transplant Congress (ATC)

    Visit the official site for the American Transplant Congress »

    American Journal of Transplantation

    The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

    American Society of Transplantation (AST)

    An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

    American Society of Transplant Surgeons (ASTS)

    The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

    Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

    Privacy Policy

    loading Cancel
    Post was not sent - check your email addresses!
    Email check failed, please try again
    Sorry, your blog cannot share posts by email.
    This site uses cookies: Find out more.